Welcome to our dedicated page for DiagnaMed Holdings news (Ticker: DGNMF), a resource for investors and traders seeking the latest updates and insights on DiagnaMed Holdings stock.
DiagnaMed Holdings Corp. reports company developments tied to its role as a Canadian technology company serving clean tech and life sciences markets, with recent updates centered on natural hydrogen initiatives. News commonly covers hydrogen extraction technology, soil-gas survey results in Ontario's Témiscamingue Graben, collaboration with Québec Innovative Materials Corp. and INRS, and agreements related to natural hydrogen development in the Ontario-Québec corridor. Other recurring updates address leadership changes, equity-incentive grants, shareholder voting matters, governance and capital-structure disclosures.
DiagnaMed Holdings Corp. (OTCQB: DGNMF) announced a leadership transition in its financial department. Jing Peng has stepped down from his position as Chief Financial Officer, effective immediately. The company has appointed Edward Low as Interim CFO, who brings significant experience in corporate finance and accounting for public companies.
Mr. Low will oversee DiagnaMed's financial operations during the transition period while the Board evaluates long-term leadership options. The company continues to focus on its hydrogen development initiatives and operational execution, particularly in Northern Ontario through its QIMC and INRS teams.
DiagnaMed Holdings Corp. (CSE: DMED) has launched a major hydrogen exploration campaign in Ontario in partnership with INRS and Quebec Innovative Materials Corp. The initiative will implement over 2,000 soil gas samples to identify high-potential natural hydrogen zones, replicating INRS-QIMC's successful exploration model from Quebec.
The exploration will be led by Dr. Marc Richer-Laflèche in collaboration with Temiscamingue First Nations. The program aims to leverage the proven geological model that demonstrated high hydrogen measurements and fault-controlled advection in Quebec. Additionally, the company announced the appointment of André Turmel to its Board of Directors, while Carlo Sansalone has stepped down.
DiagnaMed Holdings (DGNMF) has acquired 91 unpatented mineral claims totaling 1,820 hectares in Ontario's Temiscamingue hydrogen district, adjacent to Quebec Innovative Materials Corp's (QIMC) project area. The strategic acquisition positions DiagnaMed to advance its proprietary hydrogen extraction technologies in one of Canada's most promising natural hydrogen regions.
The deal terms include a $25,000 non-refundable payment and the issuance of 12.5 million common shares. The sellers receive a 2% royalty on revenues from hydrogen or mineral sales, with an option for DiagnaMed to purchase 50% of the royalty for $2 million. The acquisition aims to foster collaboration with QIMC and accelerate technology commercialization in the region.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has successfully closed its private placement offering, raising $397,510 through the issuance of 13,250,333 units at $0.03 per unit. Each unit includes one common share and one purchase warrant, allowing holders to acquire an additional share at $0.05 within 24 months.
The company paid $29,760.80 in finders' fees and issued 992,027 finder warrants. The net proceeds will fund research, development, and commercialization of their hydrogen production and monitor technology and BRAIN AGE® Brain Health AI Platform, along with general corporate purposes.
Chairman and CEO Fabio Chianelli participated in the offering, subscribing for 850,000 units ($25,500). This related party transaction is exempt from formal valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.
DiagnaMed Holdings (OTCQB: DGNMF) has received FDA Orphan Drug Designation for molecular hydrogen in treating Amyotrophic Lateral Sclerosis (ALS). This designation supports the development of treatments for this rare neuromuscular disease that affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases annually.
Molecular hydrogen, known for its antioxidant and anti-inflammatory properties, has shown promising results in preclinical studies for mitigating oxidative stress and inflammation in ALS progression. The designation provides key benefits including tax credits for clinical trials, FDA fee exemptions, and potential seven-year market exclusivity upon approval.
Additionally, DiagnaMed has entered a non-binding letter of intent with Revive Therapeutics dated February 28, 2025, to acquire full rights to DiagnaMed's intellectual property related to molecular hydrogen for ALS. The acquisition is expected to close by March 31, 2025, subject to due diligence and definitive agreement.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced a private placement offering of units, targeting between $350,000 and $510,000 at $0.03 per unit. Each unit consists of one common share and one purchase warrant, with warrants exercisable at $0.05 for 24 months from closing.
The offering, led by EMD Financial Inc, will support:
- Research, development and commercialization of hydrogen production and monitor technology
- BRAIN AGE® Brain Health AI Platform
- General corporate and working capital purposes
The company may pay finder's fees including up to 8% cash commission and 8% finder warrants. The offering, closing around March 31, 2025, will be available to Canadian residents (except Quebec) under the Listed Issuer Financing Exemption, with no resale restrictions.
DiagnaMed Holdings Corp (CSE: DMED) (OTCQB: DGNMF) has announced its support for Québec Innovative Materials Corp (QIMC) in establishing hydrogen as a primary energy source in Quebec. This initiative aligns with Quebec's goals to reduce emissions by 38% by 2030 and achieve net-zero by 2050.
The collaboration focuses on QIMC's natural hydrogen production potential in the Lake Timiskaming Graben, specifically in St-Bruno-de-Guigues. DiagnaMed will support QIMC using its proprietary electromagnetic heating technology for hydrogen extraction, developed by Dr. Qingwang Yuan at Texas Tech University's HOPE Group.
According to CEO Fabio Chianelli, QIMC's St. Bruno-de-Guigues property findings could have a potential commercial value in the billions of dollars. The company aims to produce cost-effective, carbon-neutral hydrogen using their direct extraction technology.